DesRosier Thomas's Form 4 filing
Seres Therapeutics, Inc. (MCRB) · filed Feb 18, 2026
- Accession no.
- 0001193125-26-057154
- Filed
- Feb 18, 2026
- Trade date
- Feb 15, 2026
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market sales total $660.66. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| DesRosier ThomasCIK 0001435744 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 15, 2026 | Common Stock | MOption exerciseAcquired | +244 | –F1 | – | 7,867 | Direct | |
| Feb 15, 2026 | Common Stock | SSaleDisposed | −78 | $8.47 | −$660.66 | 7,789 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 15, 2026 | Common Stock | MOption exerciseDisposed | −133 | $0.00 | $0 | 531 | Direct | |
| Feb 15, 2026 | Common Stock | MOption exerciseDisposed | −111 | $0.00 | $0 | 890 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
Referenced by the price of 1 transaction in Table I.
Remarks
Chief Legal Officer, EVP, Co-Chief Executive Officer, and Co-President